🏛️ Verified NIH Record • Updated 2026-03-03
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (NCT04900818)
A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: I-Mab Biopharma US Limited
🩺 Plain-English Summary (8th-Grade Level)
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Who can join: Review the eligibility criteria below.
Location: Stern Center for Cancer Clinical Trials and Research — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Stern Center for Cancer Clinical Trials and Research — Orange, California
- UCHealth Cancer Care - Anschutz Medical Campus — Aurora, Colorado
- Horizon Oncology Research, LLC. — Layfayette, Indiana
- Mass General Hospital — Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Carolina BioOncology Institute — Huntersville, North Carolina
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- Mary Crowley Cancer Research — Dallas, Texas
- UW Carbone Cancer Center — Madison, Wisconsin
- The Second Hospital of Anhui Medical University — Hefei, Anhui
- Beijing Cancer Hospital — Beijing, Beijing Municipality
- Sixth Affiliated Hospital, Sun Yat-sen University — Guangzhou, Guangdong
- HARBIN Medical University Cancer Hospital — Harbin, Heilongjiang
- Henan Cancer Hospital — Zhengzhou, Henan
- Hubei Cancer Hospital — Wuhan, Hubei
- The First Hospital of China Medical University — Shenyang, Liaoning
- Zhongshan Hospital, Fudan University — Shanghai, Shanghai Municipality
- Tianjin Medical University Cancer Institute and Hospital — Tianjin, Tianjin Municipality
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang
📞 Contact the Study Coordinator
Phone: (240) 745-6330
Email: us.info@imabbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.